Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus. DUALTM IX - Add-on to SGLT2i

NCT02773368 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT02773368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02773368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus. DUALTM IX - Add-on to SGLT2i
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
May 23, 2016
Completion date
October 23, 2017
Enrollment
420 (actual)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2